Michael Gelband ExodusPoint Capital Management
Michael Gelband is a co-founder of ExodusPoint Capital Management, a multi-strategy hedge fund launched by veterans of larger alternative platforms. The firm pursues diversified strategies across asset classes with a focus on risk-managed absolute returns. Gelband’s firm is followed as part of the newer generation of multi-strategy complexes.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$435M |
| 2 |
Amazon
AMZN
|
+$334M |
| 3 |
Moderna
MRNA
|
+$53.9M |
| 4 |
Linde
LIN
|
+$44.2M |
| 5 |
DTE Energy
DTE
|
+$43.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Russell 1000 Value ETF
IWD
|
+$63.6M |
| 2 |
Comcast
CMCSA
|
+$39.7M |
| 3 |
Evergy
EVRG
|
+$38.5M |
| 4 |
Public Service Enterprise Group
PEG
|
+$38.4M |
| 5 |
Bio-Techne
TECH
|
+$30.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.37% |
| 2 | Consumer Discretionary | 10.36% |
| 3 | Financials | 7.14% |
| 4 | Industrials | 6.8% |
| 5 | Healthcare | 6.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CONN
1901
DELISTED
Conn's Inc.
CONN
| $230K | ﹤0.01% |
+9,014
| New | +$208K |
|
|
ALBO
1902
DELISTED
Albireo Pharma Inc
ALBO
| $230K | ﹤0.01% |
+6,534
| New | +$212K |
|
1903
Tenet Healthcare
THC
$21.9B
| $229K | ﹤0.01% |
3,413
-9,138
| -73% | -$567K |
|
1904
eGain
EGAN
$198M
| $228K | ﹤0.01% |
+19,835
| New | +$203K |
|
1905
Fidelity MSCI Health Care Index ETF
FHLC
$3.55B
| $228K | ﹤0.01% |
+3,581
| New | +$221K |
|
1906
Select Water Solutions
WTTR
$2.45B
| $228K | ﹤0.01% |
+37,691
| New | +$218K |
|
1907
Expro Ltd
XPRO
$1.98B
| $228K | ﹤0.01% |
12,563
+10,080
| +406% | +$208K |
|
|
LTC
1908
LTC Properties
LTC
$2.19B
| $227K | ﹤0.01% |
5,921
-2,385
| -29% | -$97.1K |
|
1909
Aviat Networks
AVNW
$274M
| $226K | ﹤0.01% |
6,892
-7,232
| -51% | -$252K |
|
1910
Chunghwa Telecom
CHT
$33.5B
| $226K | ﹤0.01% |
+5,550
| New | +$226K |
|
1911
Coinbase
COIN
$49.4B
| $226K | ﹤0.01% |
+891
| New | +$231K |
|
|
DX
1912
Dynex Capital
DX
$3.23B
| $226K | ﹤0.01% |
+12,088
| New | +$237K |
|
|
VWTR
1913
DELISTED
Vidler Water Resouces, Inc. Common Stock
VWTR
| $226K | ﹤0.01% |
+16,983
| New | +$175K |
|
|
FLXN
1914
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $223K | ﹤0.01% |
27,147
-15,081
| -36% | -$128K |
|
|
TLND
1915
DELISTED
Talend S.A. American Depositary Shares
TLND
| $223K | ﹤0.01% |
+3,405
| New | +$220K |
|
1916
OFG Bancorp
OFG
$2.2B
| $222K | ﹤0.01% |
+10,039
| New | +$239K |
|
1917
Immunome
IMNM
$3.34B
| $221K | ﹤0.01% |
+12,800
| New | +$283K |
|
1918
Peapack-Gladstone Financial
PGC
$800M
| $221K | ﹤0.01% |
+7,101
| New | +$229K |
|
|
ALE
1919
DELISTED
Allete
ALE
| $220K | ﹤0.01% |
3,147
-11,086
| -78% | -$772K |
|
1920
Goldman Sachs BDC
GSBD
$1.14B
| $220K | ﹤0.01% |
+11,210
| New | +$222K |
|
|
PLYA
1921
DELISTED
Playa Hotels & Resorts
PLYA
| $220K | ﹤0.01% |
+29,656
| New | +$219K |
|
|
BCEL
1922
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $220K | ﹤0.01% |
+25,777
| New | +$264K |
|
1923
Bit Digital
BTBT
$570M
| $219K | ﹤0.01% |
+32,000
| New | +$341K |
|
1924
ProShares Online Retail ETF
ONLN
$65.1M
| $219K | ﹤0.01% |
+2,714
| New | +$213K |
|
1925
Rocky Brands
RCKY
$338M
| $219K | ﹤0.01% |
+3,934
| New | +$221K |
|
Similar funds
Michael Gelband's Q2 2021 Portfolio in Review
As of Q2 2021, Michael Gelband held 3,092 positions worth $9.04B, up 32% from $6.86B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Michael Gelband deployed $1.88B of net new capital in Q2 2021, opening 1,032 new positions and adding to 581 existing holdings. Its largest new stake was Linde: 151,692 shares worth $43.9M.
By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 13% a quarter earlier, followed by Consumer Discretionary and Financials.
On the sell side, the largest reduction was iShares Russell 1000 Value ETF, an estimated $63.6M trimmed.
- Michael Gelband's largest Q2 2021 buy was Linde: 151,692 shares worth $43.9M.
- Michael Gelband added most to Microsoft in Q2 2021, an estimated $435M increase.
- Michael Gelband's biggest Q2 2021 reduction was iShares Russell 1000 Value ETF, cutting an estimated $63.6M.
- Michael Gelband fully exited Charles River Laboratories in Q2 2021, selling an estimated $27.9M.
- Michael Gelband's ten largest holdings make up 35% of its $9.04B portfolio in Q2 2021.
- Michael Gelband opened 1,032 new positions and closed 820 in Q2 2021.
- Michael Gelband's portfolio value rose 32% quarter-over-quarter to $9.04B.
Based on ExodusPoint Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.